Table 3. Test positive results of C-Tb versus TST (top) and QFT (bottom) in non-TB participants.
All | HIV-uninfected | HIV- infected |
|
---|---|---|---|
C-Tb versus TST | |||
N | 920 | 658† | 262 |
C-Tb pos. (%) | 41.0 (37.8–44.2) |
43.6 (39.9–47.4) |
34.4 (28.9–40.3) |
TST pos. (%) | 42.5 (39.3–45.7) |
43.5 (39.7–47.3) |
40.1 (34.3–46.1) |
p-value* | 0.2980 | 1.0000 | 0.0180 |
C-Tb versus QFT | |||
N | 741 | 496‡ | 245§ |
C-Tb pos. | 46.6 (43.0–50.2) |
53.2 (48.8–57.6) |
33.1 (27.5–39.2) |
QFT pos. | 43.7 (40.2–47.3) |
52.2 (47.8–56.6) |
26.5 (21.4–32.4) |
p-value* | 0.1105 | 0.6935 | 0.0412 |
Data are presented as % (95% CI). Cut-point for TST was 5 mm in HIV-infected individuals and 15 mm in HIV-uninfected.
*McNemar’s test. In an intention to diagnose principle, QFT indeterminate results were included as negative.
†Including 97 participants (≤5 years of age) with unknown HIV status.
‡Excluding 162 with missing QFT. 15/43 QFT indeterminate results were C-Tb positives.
§17 with missing QFT. 15/68 QFT indeterminate results were C-Tb positives.